The toxicity of methotrexate in male fertility and paternal teratogenicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 13, Issue 1, 2017, Pages 51-58

  Gutierrez, Jennifer Christine ^a   Hwang, Kathleen ^b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Male infertility; methotrexate; psoriasis; rheumatoid arthritis; spermatogenesis

Indexed keywords

METHOTREXATE; ANTIRHEUMATIC AGENT;

DRUG MECHANISM; DRUG USE; HUMAN; MALE FERTILITY; MALE INFERTILITY; NONHUMAN; POLYPHARMACY; PREGNANCY OUTCOME; REVIEW; RISK ASSESSMENT; STAFF TRAINING; SYSTEMATIC REVIEW; TERATOGENICITY; TREATMENT RESPONSE; ANIMAL; CHEMICALLY INDUCED; CONGENITAL ABNORMALITIES; DRUG EFFECTS; FATHER; FEMALE; MALE; PATIENT EDUCATION; PREGNANCY; PROCEDURES; SPERM PRESERVATION; SPERMATOGENESIS; TIME FACTOR;

ANIMALS; ANTIRHEUMATIC AGENTS; CONGENITAL ABNORMALITIES; FATHERS; FEMALE; HUMANS; INFERTILITY, MALE; MALE; METHOTREXATE; PATIENT EDUCATION AS TOPIC; PREGNANCY; PREGNANCY OUTCOME; SEMEN PRESERVATION; SPERMATOGENESIS; TIME FACTORS;

EID: 85003441743     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2017.1230198     Document Type: Review

References (52)

1. Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis:2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60:824–837.
2. Mahadevan U., Fertility and pregnancy in the patient with inflammatory bowel disease. Gut. 2006;55:1198–1206.
3. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis:integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086–1093.
4. Kim YJ, Song M, Ryu JC. Mechanisms underlying methotrexate-induced pulmonary toxicity. Expert Opin Drug Saf. 2009;8:451–458.
5. Morris LF, Harrod MJ, Menter MA, Silverman AK. Methotrexate and reproduction in men:case report and recommendations. J Am Acad Dermatol. 1993;29:913–916.•• Very good discussion by a medical geneticist discussing genetic abnormalities that could lead to mutagenesis and inheritance patterns.
6. Riccardi R, Vigersky RA, Barnes S, et al. Methotrexate levels in the interstitial space and seminiferous tubule of rat testis. Cancer Res. 1982;42:1617–1619.
7. Cheng CY, Mruk DD. The blood-testis barrier and its implications for male contraception. Pharmacol Rev. 2012;64:16–64.
8. Wong CH, Cheng CY. The blood-testis barrier:its biology, regulation, and physiological role in spermatogenesis. Curr Top Dev Biol. 2005;71:263–296.
9. McDougal WS, Wein AJ, Kavoussi LR, et al. Campbell-Walsh urology eleventh edition review. 2nd ed. Philadelphia, PA:Elsevier; 2016.
10. Montesinos MC, Desai A, Delano D, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 2003;48:240–247.
11. Sukhotnik I, Nativ O, Roitburt A, et al. Methotrexate induces germ cell apoptosis and impairs spermatogenesis in a rat. Pediatr Surg Int. 2013;29:179–184.
12. Johnsen SG. Testicular biopsy score count–a method for registration of spermatogenesis in human testes:normal values and results in 335 hypogonadal males. Hormones. 1970;1:2–25.
13. Klemmt L, Scialli AR. The transport of chemicals in semen. Birth Defects Res Part B, Dev Reprod Toxicol. 2005;74:119–131.• Very good article outlining the mechanisms of exposure of the conceptus to chemicals in semen.
14. Padmanabhan S, Tripathi DN, Vikram A, et al. Cytotoxic and genotoxic effects of methotrexate in germ cells of male Swiss mice. Mutat Res. 2008;655:59–67.
15. Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy:a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66:1101–1110.
16. Hull MG, Glazener CM, Kelly NJ, et al. Population study of causes, treatment, and outcome of infertility. Br Med J (Clinical Research Ed). 1985;291:1693–1697.
17. Thonneau P, Marchand S, Tallec A, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988–1989). Hum Reprod. 1991;6:811–816.
18. Bablok L, Dziadecki W, Szymusik I, et al. Patterns of infertility in Poland–multicenter study. Neuro Endocrinol Lett. 2011;32:799–804.
19. Chiamchanya C, Su-angkawatin W. Study of the causes and the results of treatment in infertile couples at Thammasat Hospital between 1999–2004. J Med Assoc Thai. 2008;91:805–812.
20. Case AM. Infertility evaluation and management. Strategies for family physicians. Can Fam Physician. 2003;49:1465–1472.
21. Templeton A, Fraser C, Thompson B. The epidemiology of infertility in Aberdeen. BMJ (Clin Res Ed). 1990;301:148–152.
22. Grunnet E, Nyfors A, Hansen KB. Studies of human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics. Dermatologica. 1977;154:78–84.
23. Suzuki T, Shibahara H, Tsunoda H, et al. Comparison of the Sperm Quality Analyzer IIC variables with the computer-aided sperm analysis estimates. Int J Androl. 2002;25:49–54.
24. Agarwal A, Zini A, Sigman M. Is sperm DNA integrity assessment useful? J Urol. 2013;190:1645–1647.
25. Grunewald S, Paasch U, Glander HJ. Systemic dermatological treatment with relevance for male fertility. Journal der Deutschen Dermatologischen Gesellschaft = J Ger Soc Dermatol:JDDG. 2007;5:15–21.• An important article highlighting the importance of discussing cryopreservation with men exposed to cytotoxic agents.
26. Dere E, Anderson LM, Hwang K, et al. Biomarkers of chemotherapy-induced testicular damage. Fertil Steril. 2013;100:1192–1202.
27. El-Beheiry A, El-Mansy E, Kamel N, et al. Methotrexate and fertility in men. Arch Androl. 1979;3:177–179.
28. Günther E. Andrologic examinations in the antimetabolite therapy of psoriasis. Dermatol Monatsschr. 1970;156:498–502.
29. De Luca M, Ciampo E, Rossi A. Study of the seminal fluid in subjects treated with methotrexate. G Ital Dermatol Minerva Dermatol. 1971;46:247–249.
30. Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol. 1980;116:215–217.
31. Shafik A. Intratunical injection of methotrexate for the treatment of seminoma of the testicle. Anti-Cancer Drugs. 1993;4:193–195.
32. Van Scott EJ, Reinertson RP. Morphologic and physiologic effects of chemotherapeutic agents in psoriasis. J Invest Dermatol. 1959;33:357–369.
33. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol:an updated report. J Clin Oncol. 2000;18:4016–4027.
34. Hinkes E, Plotkin D. Reversible drug-induced sterility in a patient with acute leukemia. JAMA. 1973;223:1490–1491.
35. Shamberger RC, Sherins RJ, Ziegler JL, et al. Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma. J Natl Cancer Inst. 1981;67:1213–1218.
36. Rossato M, Foresta C. Antisperm antibodies in inflammatory bowel disease. Arch Intern Med. 2004;164:2283.
37. Feagins LA, Kane SV. Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterol. 2009;104:768–773.
38. Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate:an observational cohort study. Rheumatology (Oxford). 2014;53:757–763.•• One of few studies analyzing pregnancy outcomes among paternal MTX exposure.
39. Nouri HS, Azarmi Y, Movahedin M. Effect of growth hormone on testicular dysfunction induced by methotrexate in rats. Andrologia. 2009;41:105–110.
40. Saxena AK, Dhungel S, Bhattacharya S, et al. Effect of chronic low dose of methotrexate on cellular proliferation during spermatogenesis in rats. Arch Androl. 2004;50:33–35.
41. Shrestha S, Dhungel S, Saxena AK, et al. Effect of methotrexate (MTX) administration on spermatogenesis:an experimental on animal model. Nepal Med Coll J:NMCJ. 2007;9:230–233.• A good animal study detailing the changes in sperm treated with MTX.
42. Russell LD, Russell JA. Short-term morphological response of the rat testis to administration of five chemotherapeutic agents. Am J Anat. 1991;192:142–168.
43. Freeman-Narrod M, Narrod SA. Chronic toxicity of methotrexate in mice. J Natl Cancer Inst. 1977;58:735–741.
44. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4:723–730.
45. De Santis M, Cesari E, Cavaliere A, et al. Paternal exposure and counselling:experience of a Teratology Information Service. Reprod Toxicol (Elmsford, NY). 2008;26:42–46.
46. French AE, Koren G, Motherisk T. Effect of methotrexate on male fertility. Can Fam Physician. 2003;49:577–578.•• A good review of known literature regarding risks to fertility and to the fetus in men treated with MTX.
47. Beghin D, Cournot MP, Vauzelle C, et al. Paternal exposure to methotrexate and pregnancy outcomes. J Rheumatol. 2011;38:628–632.
48. Lee CY, Jin C, Mata AM, et al. A pilot study of paternal drug exposure:the Motherisk experience. Reprod Toxicol (Elmsford, NY). 2010;29:353–360.
49. Lamboglia F, D’Inca R, Oliva L, et al. Patient with severe Crohn’s disease became a father while on methotrexate and infliximab therapy. Inflamm Bowel Dis. 2009;15:648–649.
50. Perry WH. Methotrexate and teratogenesis. Arch Dermatol. 1983;119:874–875.
51. Gromnica-Ihle E, Krüger K. Use of methotrexate in young patients with respect to the reproductive system. Clin Exp Rheumatol. 2010;28:S80–A84.
52. Cordier S. Evidence for a role of paternal exposures in developmental toxicity. Basic Clin Pharmacol Toxicol. 2008;102:176–181.